Weiss Ratings Reaffirms Sell (D-) Rating for Valneva (NASDAQ:VALN)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Valneva (NASDAQ:VALN), indicating ongoing concerns about the stock's performance.
• Despite the negative rating from Weiss, Valneva has received a consensus rating of "Moderate Buy" with a target price of $15.00 from various analysts.
• Valneva's stock has shown a notable 3.6% increase recently, closing at $11.03, and has a significant trading volume with a current ratio of 2.27.

Valneva (NASDAQ:VALN - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

VALN has been the topic of a number of other research reports. Wall Street Zen upgraded Valneva to a "hold" rating in a research note on Saturday, September 6th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Valneva in a research note on Monday, August 25th. Guggenheim cut their price target on Valneva from $14.00 to $13.00 and set a "buy" rating on the stock in a research note on Monday, September 8th. Finally, Jefferies Financial Group set a $14.00 price target on Valneva and gave the stock a "buy" rating in a research note on Monday, August 25th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Valneva has a consensus rating of "Moderate Buy" and a consensus target price of $15.00.

Valneva Stock Up 3.6%

Shares of VALN traded up $0.38 during midday trading on Wednesday, reaching $11.03. 39,086 shares of the company were exchanged, compared to its average volume of 80,404. The stock has a 50-day moving average price of $9.65 and a 200-day moving average price of $7.54. Valneva has a 1-year low of $3.62 and a 1-year high of $12.25. The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. The company had revenue of $54.84 million for the quarter, compared to analysts' expectations of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. On average, analysts expect that Valneva will post 0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

Institutional investors have recently made changes to their positions in the stock. Marex Group plc bought a new position in shares of Valneva during the second quarter valued at approximately $64,000. GAMMA Investing LLC bought a new position in shares of Valneva during the first quarter valued at approximately $94,000. Finally, Frazier Life Sciences Management L.P. bought a new position in shares of Valneva during the second quarter valued at approximately $8,240,000. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.